The evolving genomic classification of lung cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions are key targets in non-small cell lung cancer (NSCLC).
• Other oncogenic drivers like ROS1, RET, MET, HER2, and BRAF are identified in NSCLC, collectively representing about 20% of cases.
• Targeted therapies have improved outcomes for patients with these specific mutations.

Purpose of the Study:

• To review the landscape of oncogenic drivers in NSCLC.
• To discuss the challenges of de novo and acquired resistance to targeted therapies.
• To highlight the need for multiplex testing strategies for personalized NSCLC treatment.

Main Methods:

• Review of current literature on NSCLC molecular targets and targeted therapies.
• Analysis of genetic complexity in NSCLC tumors.
• Discussion of emerging biomarkers and targeted agents.

Main Results:

• EGFR mutations and ALK fusions, along with other drivers, constitute approximately 20% of NSCLCs.
• Resistance to targeted therapies is a significant clinical challenge.
• NSCLC tumors often exhibit genetic complexity with multiple activating events.

Conclusions:

• Multiplex testing is crucial for identifying patients who will benefit from specific targeted agents.
• Combination strategies involving multiple targeted agents may be necessary for genetically complex tumors.
• Interpreting genomic test results alongside clinical data is essential for optimizing NSCLC treatment.